The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
NCT02126189 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2015-04-22
Summary
This study is designed to refine the aetiological causes of cancers of the head and neck and investigate the ways in which human papillomavirus and life-style factors cause head and neck cancers. This study will determine if these factors affect the treatment of cancer.
All patients attending the Head and Neck Clinic at the Princess Alexandra Hospital is invited to complete a risk factor questionnaire and give consent for their clinical data and tissue samples to be available for future research activities. The risk factor questionnaire is based on existing validated instruments developed by the QIMR Berghofer Medical Research Institute Cancer Control Group, and will collect standardised information relating to demographics and causal factors (tobacco and alcohol intake), risk modifiers (dentition, asprin and non-steroidal anti-inflammatory drugs (NSAIDS), height, weight, physical activity, diet quality etc) and behaviours (oral sex etc)
Conditions
- Head and Neck Squamous Cell Carcinoma
- Human Papillomavirus
Sponsors & Collaborators
-
QIMR Berghofer Medical Research Institute
collaborator OTHER -
Princess Alexandra Hospital, Brisbane, Australia
collaborator OTHER -
Translational Research Institute, Brisbane, Australia
collaborator UNKNOWN -
The University of Queensland
collaborator OTHER -
Queensland Centre of Excellence for Head and Neck Cancer
lead OTHER
Principal Investigators
-
Annika Antonsson, Dr · QIMR Berghofer Medical Research Institute
-
Ben Panizza, Assoc Prof · Princess Alexandra Hospital
-
Sandro Porceddu, Assoc Prof · Princess Alexandra Hospital
-
David Whiteman, Prof · QIMR Berghofer Medical Research Institute
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-11-30
- Primary Completion
- 2016-11-30
- Completion
- 2016-11-30
Countries
- Australia
Study Locations
More Related Trials
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906 ·Status: RECRUITING ·Phase: PHASE2
-
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955 ·Status: COMPLETED ·Phase: PHASE2
-
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
NCT06133790 ·Status: RECRUITING
-
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
NCT01530997 ·Status: COMPLETED ·Phase: PHASE2
-
Chemo-embolization for Head and Neck Cancer
NCT04595981 ·Status: WITHDRAWN ·Phase: PHASE2
-
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
NCT05296135 ·Status: WITHDRAWN
-
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT00358930 ·Status: COMPLETED ·Phase: PHASE2
-
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
NCT06380686 ·Status: RECRUITING
-
HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors
NCT04979000 ·Status: COMPLETED
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
NCT02031250 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT02538510 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
NCT01312350 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Registration of Head and Neck Cancer
NCT02546895 ·Status: COMPLETED
-
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
NCT05123950 ·Status: COMPLETED
-
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
NCT06597565 ·Status: RECRUITING ·Phase: PHASE2
-
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
NCT00713219 ·Status: COMPLETED ·Phase: PHASE2
-
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Circulating Tumour DNA in Head and Neck Cancer
NCT05539638 ·Status: RECRUITING
-
Anti-tumor Specific Immune Response in Head and Neck Cancers
NCT02881918 ·Status: UNKNOWN
-
Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas
NCT02279459 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NCT05283226 ·Status: RECRUITING ·Phase: PHASE2
-
The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma
NCT02916368 ·Status: UNKNOWN
-
Safety and Efficacy of APG-157 in Head and Neck Cancer
NCT05312710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2